Published in Virology on February 05, 2005
HIV-1 envelope glycoprotein biosynthesis, trafficking, and incorporation. J Mol Biol (2011) 2.01
Highly complex neutralization determinants on a monophyletic lineage of newly transmitted subtype C HIV-1 Env clones from India. Virology (2009) 1.51
Role of the membrane-spanning domain of human immunodeficiency virus type 1 envelope glycoprotein in cell-cell fusion and virus infection. J Virol (2008) 1.28
4E10-resistant variants in a human immunodeficiency virus type 1 subtype C-infected individual with an anti-membrane-proximal external region-neutralizing antibody response. J Virol (2007) 1.26
Kinetic rates of antibody binding correlate with neutralization sensitivity of variant simian immunodeficiency virus strains. J Virol (2005) 1.14
HIV-1 escape from the entry-inhibiting effects of a cholesterol-binding compound via cleavage of gp41 by the viral protease. Proc Natl Acad Sci U S A (2007) 0.92
Differential functional phenotypes of two primary HIV-1 strains resulting from homologous point mutations in the LLP domains of the envelope gp41 intracytoplasmic domain. Virology (2007) 0.86
Increased infectivity in human cells and resistance to antibody-mediated neutralization by truncation of the SIV gp41 cytoplasmic tail. Front Microbiol (2013) 0.82
Neutralization of Virus Infectivity by Antibodies: Old Problems in New Perspectives. Adv Biol (2014) 0.81
Role of the long cytoplasmic domain of the SIV Env glycoprotein in early and late stages of infection. Retrovirology (2007) 0.81
Fusogenic variants of a noncytopathic paramyxovirus. J Virol (2007) 0.76
Effects of stabilization of the gp41 cytoplasmic domain on fusion activity and infectivity of SIVmac239. AIDS Res Hum Retroviruses (2011) 0.76
Critical role for the chemokine receptor CXCR6 in NK cell-mediated antigen-specific memory of haptens and viruses. Nat Immunol (2010) 4.34
Gain-of-function experiments on H7N9. Science (2013) 3.67
Dissolving polymer microneedle patches for influenza vaccination. Nat Med (2010) 3.24
Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J Virol (2007) 2.71
Avian flu: Gain-of-function experiments on H7N9. Nature (2013) 2.32
Pause on avian flu transmission research. Science (2012) 2.24
Antigenic subversion: a novel mechanism of host immune evasion by Ebola virus. PLoS Pathog (2012) 2.09
Induction of heterosubtypic immunity to influenza virus by intranasal immunization. J Virol (2007) 2.06
Induction of long-term protective immune responses by influenza H5N1 virus-like particles. PLoS One (2009) 1.95
Immunization by vaccine-coated microneedle arrays protects against lethal influenza virus challenge. Proc Natl Acad Sci U S A (2009) 1.82
Transdermal influenza immunization with vaccine-coated microneedle arrays. PLoS One (2009) 1.78
Drugs that target dynamic microtubules: a new molecular perspective. Med Res Rev (2011) 1.70
Formulation and coating of microneedles with inactivated influenza virus to improve vaccine stability and immunogenicity. J Control Release (2009) 1.62
xMSanalyzer: automated pipeline for improved feature detection and downstream analysis of large-scale, non-targeted metabolomics data. BMC Bioinformatics (2013) 1.61
Influenza vaccines based on virus-like particles. Virus Res (2009) 1.48
Induction of influenza-specific mucosal immunity by an attenuated recombinant Sendai virus. PLoS One (2011) 1.44
Enhanced immunogenicity of stabilized trimeric soluble influenza hemagglutinin. PLoS One (2010) 1.44
Stabilization of influenza vaccine enhances protection by microneedle delivery in the mouse skin. PLoS One (2009) 1.42
Influenza virus inhibits ENaC and lung fluid clearance. Am J Physiol Lung Cell Mol Physiol (2004) 1.40
Influenza virus-like particles containing M2 induce broadly cross protective immunity. PLoS One (2011) 1.40
Protective immunity against H5N1 influenza virus by a single dose vaccination with virus-like particles. Virology (2010) 1.39
Enhanced memory responses to seasonal H1N1 influenza vaccination of the skin with the use of vaccine-coated microneedles. J Infect Dis (2010) 1.36
Incorporation of membrane-anchored flagellin into influenza virus-like particles enhances the breadth of immune responses. J Virol (2008) 1.34
Transcutaneous immunization with inactivated influenza virus induces protective immune responses. Vaccine (2006) 1.33
Ginseng and Salviae herbs play a role as immune activators and modulate immune responses during influenza virus infection. Vaccine (2006) 1.32
Virus-like particles containing multiple M2 extracellular domains confer improved cross-protection against various subtypes of influenza virus. Mol Ther (2012) 1.31
Virus-like particle vaccine protects against 2009 H1N1 pandemic influenza virus in mice. PLoS One (2010) 1.28
Three new isoforms of Caenorhabditis elegans UNC-89 containing MLCK-like protein kinase domains. J Mol Biol (2004) 1.27
Two domains that control prefusion stability and transport competence of the measles virus fusion protein. J Virol (2006) 1.26
Structural features of paramyxovirus F protein required for fusion initiation. Biochemistry (2003) 1.26
Incorporation of high levels of chimeric human immunodeficiency virus envelope glycoproteins into virus-like particles. J Virol (2007) 1.25
A bivalent influenza VLP vaccine confers complete inhibition of virus replication in lungs. Vaccine (2008) 1.24
Viruslike particle vaccine induces protection against respiratory syncytial virus infection in mice. J Infect Dis (2011) 1.24
Ebola virus-like particles produced in insect cells exhibit dendritic cell stimulating activity and induce neutralizing antibodies. Virology (2006) 1.23
Protection against lethal challenge by Ebola virus-like particles produced in insect cells. Virology (2008) 1.22
Intradermal vaccination with influenza virus-like particles by using microneedles induces protection superior to that with intramuscular immunization. J Virol (2010) 1.22
Vaccination inducing broad and improved cross protection against multiple subtypes of influenza A virus. Proc Natl Acad Sci U S A (2010) 1.22
Inhibition of influenza infection by glutathione. Free Radic Biol Med (2003) 1.20
Kinetics of immune responses to influenza virus-like particles and dose-dependence of protection with a single vaccination. J Virol (2009) 1.20
Mutations in the putative HR-C region of the measles virus F2 glycoprotein modulate syncytium formation. J Virol (2003) 1.20
Understanding metastatic SCCHN cells from unique genotypes to phenotypes with the aid of an animal model and DNA microarray analysis. Clin Exp Metastasis (2006) 1.19
A target site for template-based design of measles virus entry inhibitors. Proc Natl Acad Sci U S A (2004) 1.18
Design of a small-molecule entry inhibitor with activity against primary measles virus strains. Antimicrob Agents Chemother (2005) 1.17
Improved influenza vaccination in the skin using vaccine coated microneedles. Vaccine (2009) 1.16
Palmitoylation of the murine leukemia virus envelope protein is critical for lipid raft association and surface expression. J Virol (2002) 1.16
Human immunodeficiency virus-like particles activate multiple types of immune cells. Virology (2007) 1.16
Modified HIV envelope proteins with enhanced binding to neutralizing monoclonal antibodies. Virology (2005) 1.16
Salmonella flagellins are potent adjuvants for intranasally administered whole inactivated influenza vaccine. Vaccine (2009) 1.14
Delivery of subunit influenza vaccine to skin with microneedles improves immunogenicity and long-lived protection. Sci Rep (2012) 1.14
Nonpeptide inhibitors of measles virus entry. J Med Chem (2006) 1.08
Enhancement of mucosal immune responses by chimeric influenza HA/SHIV virus-like particles. Virology (2003) 1.07
Transmission studies resume for avian flu. Science (2013) 1.07
Intranasal immunization with influenza VLPs incorporating membrane-anchored flagellin induces strong heterosubtypic protection. PLoS One (2010) 1.06
Induction of HIV neutralizing antibodies against the MPER of the HIV envelope protein by HA/gp41 chimeric protein-based DNA and VLP vaccines. PLoS One (2011) 1.06
Dose sparing enabled by skin immunization with influenza virus-like particle vaccine using microneedles. J Control Release (2010) 1.05
Virus-like particle and DNA-based candidate AIDS vaccines. Vaccine (2003) 1.05
Surface stability and immunogenicity of the human immunodeficiency virus envelope glycoprotein: role of the cytoplasmic domain. J Virol (2004) 1.04
Single-molecule force spectroscopy reveals a stepwise unfolding of Caenorhabditis elegans giant protein kinase domains. Biophys J (2008) 1.04
Stability of influenza vaccine coated onto microneedles. Biomaterials (2012) 1.04
Stability kinetics of influenza vaccine coated onto microneedles during drying and storage. Pharm Res (2010) 1.03
Improved protection against avian influenza H5N1 virus by a single vaccination with virus-like particles in skin using microneedles. Antiviral Res (2010) 1.03
Protective effect of ginseng polysaccharides on influenza viral infection. PLoS One (2012) 1.03
Local response to microneedle-based influenza immunization in the skin. MBio (2012) 1.03
Microneedle delivery of H5N1 influenza virus-like particles to the skin induces long-lasting B- and T-cell responses in mice. Clin Vaccine Immunol (2010) 1.01
Serological memory and long-term protection to novel H1N1 influenza virus after skin vaccination. J Infect Dis (2011) 1.01
MyD88 plays an essential role in inducing B cells capable of differentiating into antibody-secreting cells after vaccination. J Virol (2011) 1.00
Titins in C.elegans with unusual features: coiled-coil domains, novel regulation of kinase activity and two new possible elastic regions. J Mol Biol (2002) 0.99
Gene and protein responses of human monocytes to extracellular cysteine redox potential. Toxicol Sci (2009) 0.99
Enhanced influenza virus-like particle vaccines containing the extracellular domain of matrix protein 2 and a Toll-like receptor ligand. Clin Vaccine Immunol (2012) 0.99
Formulation of microneedles coated with influenza virus-like particle vaccine. AAPS PharmSciTech (2010) 0.98
Immunization by influenza virus-like particles protects aged mice against lethal influenza virus challenge. Antiviral Res (2009) 0.98
Multiple heterologous M2 extracellular domains presented on virus-like particles confer broader and stronger M2 immunity than live influenza A virus infection. Antiviral Res (2013) 0.97
Influenza M1 VLPs containing neuraminidase induce heterosubtypic cross-protection. Virology (2012) 0.97
Effect of adjuvants on responses to skin immunization by microneedles coated with influenza subunit vaccine. PLoS One (2012) 0.96
Intranasal immunization with inactivated influenza virus enhances immune responses to coadministered simian-human immunodeficiency virus-like particle antigens. J Virol (2004) 0.96
Microneedle vaccination with stabilized recombinant influenza virus hemagglutinin induces improved protective immunity. Clin Vaccine Immunol (2011) 0.96
Targeting the skin for microneedle delivery of influenza vaccine. Adv Exp Med Biol (2013) 0.95
Virus-like particles as universal influenza vaccines. Expert Rev Vaccines (2012) 0.93
Immunogenicity of virus-like particles containing modified human immunodeficiency virus envelope proteins. Vaccine (2007) 0.92
Enhancement of mucosal immunization with virus-like particles of simian immunodeficiency virus. J Virol (2003) 0.92
Adjuvanted influenza vaccine administered intradermally elicits robust long-term immune responses that confer protection from lethal challenge. PLoS One (2010) 0.91
Proteomic characterization of influenza H5N1 virus-like particles and their protective immunogenicity. J Proteome Res (2011) 0.91
Stability of whole inactivated influenza virus vaccine during coating onto metal microneedles. J Control Release (2012) 0.90
Virus-like particle vaccine containing hemagglutinin confers protection against 2009 H1N1 pandemic influenza. Clin Vaccine Immunol (2011) 0.90
Influenza virus-like particles coated onto microneedles can elicit stimulatory effects on Langerhans cells in human skin. Vaccine (2010) 0.89
Enhanced mucosal immune responses to HIV virus-like particles containing a membrane-anchored adjuvant. MBio (2011) 0.89
Saccharomyces cerevisiae Npc2p is a functionally conserved homologue of the human Niemann-Pick disease type C 2 protein, hNPC2. Eukaryot Cell (2005) 0.88
Mucosal immunization with virus-like particles of simian immunodeficiency virus conjugated with cholera toxin subunit B. J Virol (2003) 0.88
Mutations in multiple domains activate paramyxovirus F protein-induced fusion. J Virol (2004) 0.88
Increased immunogenicity of avian influenza DNA vaccine delivered to the skin using a microneedle patch. Eur J Pharm Biopharm (2012) 0.88
Novel structural determinants on SIRP alpha that mediate binding to CD47. J Immunol (2007) 0.87
Murine leukemia virus R Peptide inhibits influenza virus hemagglutinin-induced membrane fusion. J Virol (2006) 0.87
DNA vaccination in the skin using microneedles improves protection against influenza. Mol Ther (2012) 0.87
Intranasal immunization with SIV virus-like particles (VLPs) elicits systemic and mucosal immunity. Vaccine (2002) 0.86
Initiation of human astrocytoma by clonal evolution of cells with progressive loss of p53 functions in a patient with a 283H TP53 germ-line mutation: evidence for a precursor lesion. Cancer Res (2002) 0.86
Delivery of DNA HIV-1 vaccine to the liver induces high and long-lasting humoral immune responses. Vaccine (2008) 0.85
Inactivation of human immunodeficiency virus type 1 by porphyrins. Antimicrob Agents Chemother (2002) 0.85
Enhancement of immunogenicity of an HIV Env DNA vaccine by mutation of the Tyr-based endocytosis motif in the cytoplasmic domain. Virology (2004) 0.85